ABT

Abbott Laboratories

Health Care

Health Care Equipment

North Chicago, Illinois

Balance Sheet 33 Accounts • 5 Years

Account	2024	2023	2022	2021	2020
end	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets - CashAndCashEquivalents	$7.6B	$6.9B	$9.9B	$9.8B	$6.8B
Assets - ShortTermInvestments	$351.0M	$383.0M	$288.0M	$450.0M	$310.0M
Assets - AccountsReceivable	$6.9B	$6.6B	$6.2B	$6.5B	$6.4B
Assets - Inventories	$6.2B	$6.6B	$6.2B	$5.2B	$5.0B
Assets - TotalCurrentAssets	$23.7B	$22.7B	$25.2B	$24.2B	$20.4B
Assets - Property,PlantAndEquipment	$10.7B	$10.2B	$9.2B	$9.0B	$9.0B
Assets - Goodwill	$23.1B	$23.7B	$22.8B	$23.2B	$23.7B
Assets - IntangibleAssets(net,ExcludingGoodwill)	$6.6B	$8.8B	$10.5B	$12.7B	$14.8B
Assets - OperatingLeaseAssets	$1.1B	$1.1B	$1.1B	$1.2B	$1.1B
Assets - DeferredTaxAssets	$10.4B	$2.9B	$2.7B	$2.8B	$3.2B
Assets - LongTermInvestments	$886.0M	$799.0M	$766.0M	$816.0M	$821.0M
Assets - TotalNoncurrentAssets	$18.5B	$16.2B	$14.2B	$13.1B	$11.7B
Assets - TotalAssets	$81.4B	$73.2B	$74.4B	$75.2B	$72.5B
Liabilities - AccountsPayable	$4.2B	$4.3B	$4.6B	$4.4B	$3.9B
Liabilities - AccruedLiabilities	$5.1B	$5.4B	$5.8B	$5.2B	$5.2B
Liabilities - ContractLiabilitiesCurrent	$568.0M	$545.0M	$500.0M	$520.0M	$405.0M
Liabilities - ShortTermDebtAndCurrentPortionOfLongTermDebt	$1.5B	$1.1B	$2.3B	$754.0M	$7.0M
Liabilities - OperatingLeaseLiabilitiesCurrent	$254.0M	$245.0M	$230.0M	$245.0M	$241.0M
Liabilities - TotalCurrentLiabilities	$14.2B	$13.8B	$15.5B	$13.1B	$11.9B
Liabilities - LongTermDebt	$12.6B	$13.6B	$14.5B	$17.3B	$18.5B
Liabilities - OperatingLeaseLiabilitiesNoncurrent	$896.0M	$949.0M	$943.0M	$956.0M	$902.0M
Liabilities - DeferredTaxLiabilitiesNoncurrent	$2.3B	$2.4B	$2.7B	$3.0B	$3.4B
Liabilities - PensionAndOtherPostretirementBenefitsLiabilitiesNoncurrent	$1.9B	$2.0B	$1.8B	$2.7B	$3.1B
Liabilities - OtherNoncurrentLiabilities	$3.4B	$3.5B	$3.8B	$3.7B	$1.2B
Equity - PreferredStock	$0	$0	$0	$0	$1.0M
Equity - CommonStock	$25.2B	$24.9B	$24.7B	$24.5B	$24.1B
Equity - RetainedEarnings(deficit)	$47.3B	$37.6B	$35.3B	$31.5B	$27.6B
Equity - TreasuryStock	$16.8B	$16.0B	$15.2B	$11.8B	$10.0B
Equity - AccumulatedOtherComprehensiveIncome(loss)	$-7.9B	$-7.8B	$-8.1B	$-8.4B	$-8.9B
Equity - NoncontrollingInterest(permanentEquity)	$237.0M	$224.0M	$219.0M	$222.0M	$219.0M
Equity - TotalStockholdersEquity	$47.7B	$38.6B	$36.7B	$35.8B	$32.8B
Equity - TotalLiabilitiesAndStockholdersEquity	$81.4B	$73.2B	$74.4B	$75.2B	$72.5B

Income Statement 21 Accounts • 5 Years

Account	2024	2023	2022	2021	2020
end	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
IncomeStatement - Revenues - NetRevenues/Sales	$42.0B	$40.1B	$43.7B	$43.1B	$34.6B
IncomeStatement - CostsAndExpenses - CostOfGoodsSold/CostOfSales	$18.7B	$18.0B	$19.1B	$18.5B	$15.0B
IncomeStatement - CostsAndExpenses - ResearchAndDevelopmentExpense	$2.8B	$2.7B	$2.9B	$2.7B	$2.4B
IncomeStatement - CostsAndExpenses - Selling,GeneralAndAdministrative	$11.7B	$10.9B	$11.2B	$11.3B	$9.7B
IncomeStatement - CostsAndExpenses - AmortizationOfIntangibleAssets(operating)	$1.9B	$2.0B	$2.0B	$2.0B	$2.1B
IncomeStatement - CostsAndExpenses - Depreciation(operating)	$1.3B	$1.3B	$1.3B	$1.5B	$1.2B
IncomeStatement - CostsAndExpenses - RestructuringAndImpairmentCharges	$0	$0	$0	$0	$36.0M
IncomeStatement - OtherIncomeExpense - OperatingIncome(loss)	$6.8B	$6.5B	$8.4B	$8.4B	$5.4B
IncomeStatement - OtherIncomeExpense - InterestIncome	$344.0M	$385.0M	$183.0M	$43.0M	$46.0M
IncomeStatement - OtherIncomeExpense - OtherNonoperatingIncome(expense)	$376.0M	$479.0M	$321.0M	$277.0M	$103.0M
IncomeStatement - OtherIncomeExpense - Income(loss)FromContinuingOperationsBeforeIncomeTaxes	$7.0B	$6.7B	$8.3B	$8.2B	$5.0B
IncomeStatement - IncomeTax - IncomeTaxExpense(benefit)	$-6.4B	$941.0M	$1.4B	$1.1B	$497.0M
IncomeStatement - IncomeTax - EffectiveTaxRate(continuingOperations)	$-1	$0	$0	$0	$0
IncomeStatement - NetIncomeAndEps - NetIncome(loss)	$13.4B	$5.7B	$6.9B	$7.1B	$4.5B
IncomeStatement - NetIncomeAndEps - NetIncome(loss)AttributableToCompany	$13.4B	$5.7B	$6.9B	$7.0B	$4.5B
IncomeStatement - NetIncomeAndEps - BasicEarningsPerShare(net)	$8	$3	$4	$4	$3
IncomeStatement - NetIncomeAndEps - DilutedEarningsPerShare(net)	$8	$3	$4	$4	$2
IncomeStatement - NetIncomeAndEps - WeightedAverageSharesOutstandingBasic	$1.7B	$1.7B	$1.8B	$1.8B	$1.8B
IncomeStatement - NetIncomeAndEps - WeightedAverageSharesOutstandingDiluted	$1.7B	$1.7B	$1.8B	$1.8B	$1.8B
IncomeStatement - NetIncomeAndEps - ComprehensiveIncome(loss)	$13.3B	$5.9B	$7.3B	$7.6B	$4.0B

Cash Flow Statement 24 Accounts • 5 Years

Account	2024	2023	2022	2021	2020
end	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
CashFlow - OperatingActivities - NetIncome	$13.4B	$5.7B	$6.9B	$7.1B	$4.5B
CashFlow - OperatingActivities - DepreciationAndAmortization	$1.3B	$1.3B	$1.3B	$1.5B	$1.2B
CashFlow - OperatingActivities - ShareBasedCompensation	$673.0M	$644.0M	$685.0M	$640.0M	$546.0M
CashFlow - OperatingActivities - DeferredIncomeTaxes	$-8.0B	$-461.0M	$-659.0M	$-509.0M	$-108.0M
CashFlow - OperatingActivities - ProvisionForDoubtfulAccounts	$61.0M	$26.0M	$6.0M	$51.0M	$88.0M
CashFlow - OperatingActivities - ImpairmentCharges(nonCash)	$0	$0	$0	$0	$0
CashFlow - OperatingActivities - ChangesInOperatingAssetsAndLiabilities	$-6.1B	$-215.0M	$1.6B	$1.5B	$3.2B
CashFlow - OperatingActivities - CashFromOperatingActivities(continuingOperations)	$8.6B	$7.3B	$9.6B	$10.5B	$7.9B
CashFlow - InvestingActivities - CapitalExpenditures(pp&e)	$2.2B	$2.2B	$1.8B	$1.9B	$2.2B
CashFlow - InvestingActivities - PurchasesOfInvestments/marketableSecurities	$169.0M	$159.0M	$185.0M	$173.0M	$83.0M
CashFlow - InvestingActivities - ProceedsFromDivestitureOfBusinesses/assets	$1.0M	$40.0M	$48.0M	$134.0M	$58.0M
CashFlow - InvestingActivities - OtherInvestingActivities	$-9.0M	$-22.0M	$-22.0M	$-26.0M	$-19.0M
CashFlow - InvestingActivities - CashFromInvestingActivities(continuingOperations)	$-2.3B	$-3.1B	$-1.7B	$-2.0B	$-2.2B
CashFlow - FinancingActivities - ProceedsFromIssuanceOfDebt	$-100.0M	$21.0M	$47.0M	$4.0M	$1.3B
CashFlow - FinancingActivities - PaymentsForRepurchaseOfCommonStock	$1.3B	$1.2B	$3.8B	$2.3B	$403.0M
CashFlow - FinancingActivities - PaymentOfDividends	$3.8B	$3.6B	$3.3B	$3.2B	$2.6B
CashFlow - FinancingActivities - ProceedsFromStockOptionsExercised/SharePlans	$264.0M	$167.0M	$167.0M	$255.0M	$245.0M
CashFlow - FinancingActivities - CashFromFinancingActivities(continuingOperations)	$-5.4B	$-7.1B	$-7.6B	$-5.5B	$-2.8B
CashFlow - CashReconciliationAndSupplemental - EffectOfExchangeRateChangesOnCash	$-96.0M	$-23.0M	$-122.0M	$-70.0M	$71.0M
CashFlow - CashReconciliationAndSupplemental - NetChangeInCash	$720.0M	$-3.0B	$83.0M	$3.0B	$3.0B
CashFlow - CashReconciliationAndSupplemental - IncomeTaxesPaid	$1.7B	$1.5B	$1.9B	$1.9B	$970.0M
CashFlow - CashReconciliationAndSupplemental - InterestPaid	$604.0M	$662.0M	$563.0M	$544.0M	$549.0M
CashFlow - CashReconciliationAndSupplemental - RightOfUseAssetsObtainedForLeases(nonCash)	$253.0M	$253.0M	$263.0M	$343.0M	$396.0M

Abbott Laboratories

Balance Sheet 33 Accounts • 5 Years

Income Statement 21 Accounts • 5 Years

Cash Flow Statement 24 Accounts • 5 Years

Stock Market Data (1 Year) Live Yahoo Finance Data

Recent Price History